IS2039B - Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum - Google Patents

Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum

Info

Publication number
IS2039B
IS2039B IS5321A IS5321A IS2039B IS 2039 B IS2039 B IS 2039B IS 5321 A IS5321 A IS 5321A IS 5321 A IS5321 A IS 5321A IS 2039 B IS2039 B IS 2039B
Authority
IS
Iceland
Prior art keywords
enhancement method
ige antibodies
polypeptide
improved
polypeptide enhancement
Prior art date
Application number
IS5321A
Other languages
English (en)
Icelandic (is)
Other versions
IS5321A (is
Inventor
B. Lowman Henry
G. Presta Leonard
M. Jardieu Paula
Lowe John
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of IS5321A publication Critical patent/IS5321A/is
Publication of IS2039B publication Critical patent/IS2039B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
IS5321A 1997-07-02 1999-12-23 Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum IS2039B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/887,352 US5994511A (en) 1997-07-02 1997-07-02 Anti-IgE antibodies and methods of improving polypeptides
PCT/US1998/013410 WO1999001556A2 (en) 1997-07-02 1998-06-30 IMPROVED ANTI-IgE ANTIBODIES AND METHOD OF IMPROVING POLYPEPTIDES

Publications (2)

Publication Number Publication Date
IS5321A IS5321A (is) 1999-12-23
IS2039B true IS2039B (is) 2005-08-15

Family

ID=25390964

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5321A IS2039B (is) 1997-07-02 1999-12-23 Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum

Country Status (29)

Country Link
US (4) US5994511A (es)
EP (1) EP0996728B1 (es)
JP (2) JP4286327B2 (es)
KR (1) KR100547538B1 (es)
CN (1) CN1260357C (es)
AR (2) AR013169A1 (es)
AT (1) ATE253116T1 (es)
AU (1) AU741115B2 (es)
BR (2) BRPI9810654C1 (es)
CA (1) CA2295540C (es)
CZ (1) CZ300724B6 (es)
DE (1) DE69819332T2 (es)
DK (1) DK0996728T3 (es)
ES (1) ES2210778T3 (es)
HK (1) HK1027833A1 (es)
HU (1) HU228845B1 (es)
IL (2) IL133973A0 (es)
IS (1) IS2039B (es)
NO (1) NO324992B1 (es)
NZ (1) NZ501842A (es)
PL (1) PL194562B1 (es)
PT (1) PT996728E (es)
RO (1) RO120848B1 (es)
RU (1) RU2242515C2 (es)
SK (1) SK284395B6 (es)
TR (1) TR200000206T2 (es)
TW (2) TWI233946B (es)
WO (1) WO1999001556A2 (es)
ZA (1) ZA985500B (es)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20040146507A1 (en) * 1996-11-27 2004-07-29 Genentech, Inc. Antibody mutants
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7759133B2 (en) * 1998-12-22 2010-07-20 Alk-Abello A/S Method of detecting and/or quantifying a specific IgE antibody in a liquid sample
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays
WO2001044441A1 (en) * 1999-12-14 2001-06-21 Thermo Biostar, Inc. Stabilizing diluent for polypeptides and antigens
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7018801B2 (en) * 2000-02-11 2006-03-28 Board Of Regents, The University Of Texas System Selection of peptides with antibody-like properties
EP1270596A4 (en) * 2000-04-07 2003-06-04 Matsushita Electric Ind Co Ltd ANTIBODY-CARRIER COMPLEX, METHOD OF ITS PRODUCTION, METHOD FOR CONTROLLING ANTIQUE-ANTIBODY REACTION BY USING THE COMPLEX AND IMMUNASSAY METHOD
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002072141A2 (en) * 2001-03-09 2002-09-19 William Herman Targeted ligands
US6966992B2 (en) * 2001-03-19 2005-11-22 Akzo Nobel Nv Method of purification of molecules using unbranched terminal alkyldiols
US6955717B2 (en) * 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
US20040146502A1 (en) * 2001-05-03 2004-07-29 Elisabeth Latour Use of organic compounds
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030087372A1 (en) * 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US20030073249A1 (en) * 2001-07-07 2003-04-17 Lee Duen Allergen detection chip
JP2003137804A (ja) * 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2003057881A1 (fr) * 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
EP1461001A4 (en) * 2002-01-03 2010-03-31 Scripps Research Inst EPITOPE ASSOCIATED WITH CANCER
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
US20040018573A1 (en) * 2002-04-18 2004-01-29 Power Scott D Production of functional antibodies in filamentous fungi
CA2490659C (en) * 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
JP2006519763A (ja) * 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
EP1558650A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
ES2551682T3 (es) * 2002-11-08 2015-11-23 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
JP4764334B2 (ja) * 2003-02-01 2011-08-31 タノックス インコーポレーテッド 高親和性抗ヒトＩｇＥ抗体
ATE486936T1 (de) * 2003-03-05 2010-11-15 Chemo Sero Therapeut Res Inst Verfahren zur herstellung eines heterologen proteins in e. coli
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4134166B2 (ja) * 2003-04-30 2008-08-13 独立行政法人科学技術振興機構 ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
WO2005023831A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Detection of cholesterol ozonation products
CA2537976A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Ozonation products of cholesterol for the treatment and prevention of artherosclerosis and/or cardiovascular diseases
JP2008500269A (ja) * 2003-10-08 2008-01-10 イーバイオサイエンス 天然免疫グロブリン結合試薬とその作製及び使用方法
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
EP1735453A2 (en) * 2004-03-12 2006-12-27 The Scripps Research Institute Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities
JPWO2005090405A1 (ja) * 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
MX2007000891A (es) 2004-07-23 2007-04-18 Genentech Inc Cristalizacion de anticuerpos o fragmentos de ellos.
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP2008515806A (ja) * 2004-10-05 2008-05-15 タノックス インコーポレイテッド 代償療法を受けている患者における過敏症および／またはアナフィラキシーの抗ＩｇＥ抗体による処置および予防
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2007124933A (ru) * 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
EP2351841A1 (en) 2005-03-25 2011-08-03 National Research Council of Canada Method for isolation of soluble polypeptides
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
US8080249B2 (en) * 2005-06-30 2011-12-20 Risk Glifford G Methods to treating chronic obstructive pulmonary disease
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
CN101062949B (zh) * 2006-04-26 2011-07-27 上海抗体药物国家工程研究中心有限公司 重组抗人IgE单克隆抗体及其制备方法和用途
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
CN101522219A (zh) * 2006-10-12 2009-09-02 惠氏公司 改变抗体溶液中离子强度以减少乳光/聚集物
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2121762A1 (en) * 2007-02-15 2009-11-25 AstraZeneca AB BINDING MEMBERS FOR IgE MOLECULES
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
UY30994A1 (es) * 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
PL2155783T5 (pl) † 2007-04-03 2023-03-13 Amgen Research (Munich) Gmbh Swoista międzygatunkowo domena wiążąca CD3epsilon
EP2155788B1 (en) * 2007-04-03 2012-06-27 Micromet AG Cross-species-specific bispecific binders
US20100113294A1 (en) * 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
CA2683568A1 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
ES2666170T3 (es) 2007-10-30 2018-05-03 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
CA2719924C (en) * 2008-04-11 2017-10-03 Philip Tan Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
IT1391559B1 (it) * 2008-09-01 2012-01-11 Lofarma Spa Allergoidi derivati da allergeni
EP2853545B8 (en) 2008-09-17 2023-04-05 Xencor, Inc. Antibody specific for IgE
RU2553214C2 (ru) 2008-10-29 2015-06-10 Аблинкс Н.В. Способы очистки однодоменных антигенсвязывающих молекул
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
CA2743487A1 (en) * 2008-11-13 2010-05-20 Emergent Product Development Seattle, Llc Cd37 immunotherapeutic combination therapies and uses thereof
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
RU2011140498A (ru) * 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
JP6139885B2 (ja) * 2009-10-26 2017-05-31 ジェネンテック， インコーポレイテッド 治療的抗ＩｇＥ抗体に特異的な抗体を検出するためのアッセイ及びアナフィラキシーにおけるそれらの使用
EP3345615B1 (en) 2010-03-01 2019-10-16 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SA111320266B1 (ar) * 2010-03-11 2015-06-21 رينات نيوروساينس كوربوريشن أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
KR101878369B1 (ko) 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
WO2011146394A1 (en) 2010-05-17 2011-11-24 Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
CN104998254A (zh) 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
WO2013120973A1 (en) * 2012-02-15 2013-08-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of producing high-affinity antibodies
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US20130309226A1 (en) 2012-05-18 2013-11-21 Genentech, Inc. High-concentration monoclonal antibody formulations
US20150140608A1 (en) * 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2895197B1 (en) 2012-09-12 2020-02-26 Ramot at Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CN105873953A (zh) 2013-11-04 2016-08-17 格兰马克药品股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
RU2689761C1 (ru) 2013-11-13 2019-05-28 Дженентек, Инк. Устройства и способы для ручного инъектирования с усилием
TW201623337A (zh) 2014-05-01 2016-07-01 建南德克公司 抗－因子ｄ抗體變異體及其用途
AU2015277379B2 (en) * 2014-06-17 2017-06-29 Academia Sinica Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells
EP3777535A1 (en) 2014-07-09 2021-02-17 F. Hoffmann-La Roche AG Ph adjustment to improve thaw recovery of cell banks
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016164920A1 (en) 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US11708421B2 (en) 2016-07-18 2023-07-25 Ramot At Tel-Aviv University Ltd. Modular platform for targeted therapeutics
CA3041717A1 (en) * 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
CN110049778A (zh) 2016-12-22 2019-07-23 豪夫迈·罗氏有限公司 减少冻干多肽重构时间的方法和制剂
EP3624846A1 (en) 2017-05-16 2020-03-25 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
PT3587445T (pt) * 2017-08-10 2024-03-14 Grifols Diagnostic Solutions Inc Um marcador de oligomerização compreendendo uma região fc de imunoglobulina e um domínio poli-his
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ
KR20230142806A (ko) 2018-02-09 2023-10-11 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
KR20230042030A (ko) * 2020-07-10 2023-03-27 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 항-IgE 조작된 항체 및 이의 적용
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6031471B2 (ja) * 1978-07-21 1985-07-22 協和醗酵工業株式会社 グリセロ−ル酸化酵素およびその製法
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ATE164395T1 (de) * 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE233813T1 (de) * 1991-08-14 2003-03-15 Genentech Inc Veränderte immunglobuline für spezifische fc- epsilon rezeptoren
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
EP0617706B1 (en) * 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69334255D1 (de) * 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
WO1994020533A1 (en) 1993-03-11 1994-09-15 Tanox Biosystems, Inc. PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2229140A1 (en) * 1995-08-17 1997-02-27 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides

Also Published As

Publication number Publication date
HK1027833A1 (en) 2001-01-23
US20020054878A1 (en) 2002-05-09
PL194562B1 (pl) 2007-06-29
AU741115B2 (en) 2001-11-22
KR20010014422A (ko) 2001-02-26
ZA985500B (en) 1999-12-24
TWI233946B (en) 2005-06-11
WO1999001556A2 (en) 1999-01-14
JP2009055902A (ja) 2009-03-19
AU8270198A (en) 1999-01-25
TR200000206T2 (tr) 2000-07-21
CA2295540C (en) 2011-01-25
NO324992B1 (no) 2008-01-14
CZ473599A3 (cs) 2000-06-14
DE69819332T2 (de) 2004-07-15
AR060038A2 (es) 2008-05-21
IL133973A0 (en) 2001-04-30
ES2210778T3 (es) 2004-07-01
US6682735B2 (en) 2004-01-27
WO1999001556A3 (en) 1999-04-22
JP4286327B2 (ja) 2009-06-24
DK0996728T3 (da) 2004-02-23
NZ501842A (en) 2002-02-01
EP0996728B1 (en) 2003-10-29
US6761889B2 (en) 2004-07-13
IS5321A (is) 1999-12-23
BRPI9810654C1 (pt) 2021-05-25
HUP0002474A2 (hu) 2000-10-28
DE69819332D1 (de) 2003-12-04
SK187599A3 (en) 2001-08-06
US6290957B1 (en) 2001-09-18
CN1268176A (zh) 2000-09-27
TW570976B (en) 2004-01-11
PT996728E (pt) 2004-03-31
HUP0002474A3 (en) 2003-03-28
HU228845B1 (en) 2013-06-28
BR9810654B8 (pt) 2013-02-19
US5994511A (en) 1999-11-30
US20030149244A1 (en) 2003-08-07
RO120848B1 (ro) 2006-08-30
KR100547538B1 (ko) 2006-01-31
CA2295540A1 (en) 1999-01-14
NO996551L (no) 2000-03-01
CZ300724B6 (cs) 2009-07-29
PL338030A1 (en) 2000-09-25
NO996551D0 (no) 1999-12-29
JP4371248B2 (ja) 2009-11-25
BR9810654B1 (pt) 2013-01-08
SK284395B6 (sk) 2005-03-04
CN1260357C (zh) 2006-06-21
AR013169A1 (es) 2000-12-13
JP2002510211A (ja) 2002-04-02
IL133973A (en) 2006-12-10
BR9810654A (pt) 2005-10-04
ATE253116T1 (de) 2003-11-15
EP0996728A2 (en) 2000-05-03
RU2242515C2 (ru) 2004-12-20

Similar Documents

Publication Publication Date Title
IS5321A (is) Bætt mótefni gegn IgE og aðferð til endurbóta á fjölpeptíðum
NO20071415L (no) OB-fusjonsproteinpreparater og fremgangsmater
NO985339D0 (no) Humane B-celleantigener og beslektede reagenser
NO20000700D0 (no) Interleukin-18-proteiner samt fremstilling og anvendelse derav
NO20001568L (no) Laserjiggesystem og fremgangsmÕte til bruk for sammenstilling av fagverk
NO985278L (no) Elektromagnetiske-til-akustiske og akustiske-til-elektro-magnetiske forsterkere og fremgangsmÕter for bruk av disse
CY2010017I2 (el) Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης
DE69427123T2 (de) Screeningverfahren für katalytische nicht-enzym-polypeptide und-proteine
DK0894135T3 (da) Multivalent og multispecifikt antigenbindingsprotein
IS5525A (is) Innúðabúnaður og aðferð
NO981426D0 (no) Fremgangsmåte og anordning for primær-brönn-sementering
NO971847D0 (no) Diffusjonsbindingsfremgangsmåte og diffusjonsbindingsapparat
NO976122L (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
DK0910233T3 (da) Afskærmet PC-kort og fremgangsmåde til fremstilling
DK0870148T3 (da) Hurtig-til-/fra-kobling og fremgangsmåde og indretning til samling deraf
NO305095B1 (no) FremgangsmÕte og anordning for forsegling
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
NO971448D0 (no) Anti-Fas rekombinante antistoffer og DNA derfor
IS5156A (is) Aðferð og búnaður til að framkalla þéttlokun
DK0970465T3 (da) Indretning og fremgangsmåde til prosodigenerering til visuel syntese
NO982181D0 (no) Type IX collagen og chimerer
NO905561D0 (no) Proteiner og nukleinsyrer.
DK1707621T3 (da) Muteret bioluminescerende protein og fremgangsmåde til fremstilling af det muterede bioluminiscerende protein
NO993102D0 (no) Chipkort og fremgangsmÕte ved anvendelse av chipkortet
NO993506D0 (no) Roerfundament og fremgangsmåte for tilvirkning av dette